Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06224413
Recruiting Observational

A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

NCT06224413 · tracked via the Priya Life Science USA tracker
Sponsor
Genetix Biotherapeutics Inc
Phase
Observational
Started
2024-03-27
Last updated
2025-07-02

Condition(s) studied

Cerebral Adrenoleukodystrophy (CALD)

Investigational drug(s) / intervention(s)

No Intervention

No Intervention: This is non-interventional study.

Study summary

The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time in participants with more advanced early active CALD. All enrolled participants with CALD treated with eli-cel in the post-marketing setting will be followed in this study for 15 years. No investigational drug product will be administered in this study. This study will enroll 120 participants with CALD treated with eli-cel in the post-marketing setting. A subpopulation of 24 participants with more advanced early active CALD will be specifically enrolled as required by the US FDA as a condition of accelerated approval and will be considered as a separate cohort for effectiveness outcomes.

Eligibility

Sex
MALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: Participants who fulfill the following criteria will be eligible for inclusion in this Registry Study. * Participant must be treated with eli-cel in the post marketing setting at a center in the United States (US) that participates in the Registry Study. * Participant must have provided an informed consent and/or assent to participate in Center for International Blood and Marrow Transplant Research (CIBMTR) registry. * Participant must have provided an informed consent and/or assent to participate in the Registry Study. * Participant must receive follow up care by a US-based physician with the ability to submit REG-502 data. Registry Study Subpopulation inclusion: Twenty-four of the 120 patients in the Registry Study must meet the following inclusion criteria which will be used to create the more advanced early active CALD subpopulation: • Participant must meet the above inclusion criteria and have a Loes score of 4.5 through 9.0 with GdE+ (gadolinium enhancement positivity) from an MRI performed before treatment with eli-cel and with NFS of 0 or 1 at baseline. Exclusion Criteria: There are no exclusion criteria for this Registry Study.

Primary outcome measure(s)

  • Number of Participants who Experience Each Individual Adverse Events of Interest (AEIs) — Through 15 years postinfusion
    The Sponsor considers the following events to be AEIs (which should be reported as a medically significant Serious Adverse Events \[SAEs\]): * Any newly diagnosed malignancy * Neutrophil engraftment failure: defined as health care provider (HCP) decision to administer back-up cells or subsequent hematopoietic stem cell transplantation (HSCT) due to neutrophil recovery failure * Newly acquired HIV-1 or HIV-2 infection * Any newly diagnosed autoimmune disorders * Opportunistic infections * Grade 3 or higher cytopenias occurring more than 60 days after eli-cel infusion
  • Number of Participants with Newly Diagnosed Malignancies — Through 15 years postinfusion
  • Number of Participants with Insertional Oncogenesis — Through 15 years postinfusion
  • Major Functional Disability (MFD)-Free Survival — Through 15 years postinfusion
    MFD-free survival is defined as time from drug product infusion to either a rescue cell administration or second transplant, MFD, or death due to any cause, whichever occurs first.

Trial sites (3)

FacilityCityRegionStatus
Boston Children's Hospital Boston Massachusetts Recruiting
Children's Hospital of Philadelphia Philadelphia Pennsylvania Recruiting
UT Southwestern Medical Center Dallas Texas Recruiting

More Genetix Biotherapeutics Inc. trials in the USA

Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy Enrolling by invitation
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease Active, not recruiting
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Active, not recruiting
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy Active, not recruiting
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel Recruiting

Other trials for the same condition

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Active, not recruiting
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06224413 on ClinicalTrials.gov ↗ ← All trials in the USA